Article
Hematology
Sara Beygi, George E. Duran, Sebastian Fernandez-Pol, Alain H. Rook, Youn H. Kim, Michael S. Khodadoust
Summary: Resistance to mogamulizumab in mycosis fungoides and Sezary syndrome is often associated with loss of CCR4 expression and emergence of CCR4 genomic alterations. This finding has significant implications for the management and monitoring of patients receiving mogamulizumab and the development of future CCR4-directed therapies.
Review
Cell Biology
Amy Xiao, Oleg E. Akilov
Summary: The loss of CD47 on aging cells signals macrophages to eliminate the target. CD47 acts as a "do-not-eat-me" sign that prevents macrophagal phagocytosis by interacting with its ligand SIRP alpha. Malignant lymphocytes highly express CD47, making them ideal candidates for targeted anti-CD47 therapies. There are various types of anti-CD47-SIRP alpha therapeutic molecules, including monoclonal antibodies, bioengineered proteins, miRNAs, and bispecific antibodies. Blocking the CD47-SIRP alpha axis in combination with targeting secondary tumor microenvironment (TME) may enhance the effectiveness of current immunotherapeutic approaches.
Review
Oncology
Kalyani Patil, Shilpa Kuttikrishnan, Abdul Q. Khan, Fareed Ahmad, Majid Alam, Joerg Buddenkotte, Aamir Ahmad, Martin Steinhoff, Shahab Uddin
Summary: Cutaneous T cell lymphomas (CTCLs) are a diverse group of lymphoproliferative neoplasms with varying immune, clinical, and histopathological features. Recent studies have used next-generation sequencing (NGS) to reveal genetic and epigenetic abnormalities that contribute to the development of CTCL. Malignant T cell clones in CTCL patients secrete cytokines and chemokines, creating a tumor microenvironment that favors T helper 2 (Th2)-type immune responses and promotes immune dysregulation and tumor growth. Understanding the molecular mechanisms, including the role of cytokines, chemokines, and signaling networks, in CTCL pathogenesis can lead to new therapeutic approaches.
SEMINARS IN CANCER BIOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Minami Sakamoto, Tomomitsu Miyagaki, Hiroaki Kamijo, Tomonori Oka, Hikari Boki, Naomi Takahashi-Shishido, Hiraku Suga, Makoto Sugaya, Shinichi Sato
Summary: CD147 and CypA are overexpressed in tumor cells of mycosis fungoides and Sezary syndrome patients, and CypA is also expressed by epidermal keratinocytes in lesional skin. Serum CypA levels are elevated and correlated with disease severity markers. Anti-CD147 and/or anti-CypA antibodies can suppress the proliferation of CTCL cell lines by downregulating signaling pathways.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Multidisciplinary Sciences
Xiangjun Liu, Shanzhao Jin, Simeng Hu, Ruoyan Li, Haihao Pan, Yi Liu, Pan Lai, Deshu Xu, Jingru Sun, Ziyang Liu, Yumei Gao, Yifan Zhao, Fengjie Liu, Yu Xiao, Yingyi Li, Yujie Wen, Zhuojing Chen, Bufang Xu, Yuchieh Lin, Menglong Ran, Qianxi Li, Shuxia Yang, Hang Li, Ping Tu, Muzlifah Haniffa, Sarah A. Teichmann, Fan Bai, Yang Wang
Summary: Cutaneous T cell lymphoma (CTCL) is a heterogeneous group of non-Hodgkin lymphoma characterized by clonal malignant T cells. This study analyzed CTCL patient samples using single-cell RNA-seq, TCR and whole-exome sequencing, revealing the molecular profiles of malignant T cells and their association with the microenvironment and clinical outcomes.
NATURE COMMUNICATIONS
(2022)
Article
Oncology
Delice Kayishunge, Sophia Ly, Joseph Su, Henry K. Wong
Summary: This article presents a demographic and epidemiological analysis of CTCL patients in Arkansas and nationwide. The study found that CTCL primarily affects males, especially young black males. Additionally, the study identified certain geographic and environmental factors associated with CTCL.
Article
Dermatology
Sara Peru, Martina Prochazkova-Carlotti, Floriane Cherrier, Joanne Velazquez, Elodie Richard, Yamina Idrissi, David Cappellen, Lamia Azzi-Martin, Anne Pham-Ledard, Marie Beylot-Barry, Jean-Philippe Merlio, Sandrine Poglio
Summary: Cutaneous T-cell lymphoma (CTCL) is characterized by abnormal infiltration of T lymphocytes in the skin. In this study, the researchers found that the expression of cutaneous lymphocyte antigen (CLA) in CTCL cells is crucial for their migration and survival. The use of a CLA antibody significantly reduced the migration and survival of CTCL cells both in vitro and in vivo. These findings suggest that inhibiting CLA could be a potential therapeutic strategy for CTCL patients.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2022)
Article
Dermatology
Janika Gosmann, Rudolf Stadler, Koen D. Quint, Ralf Gutzmer, Maarten H. Vermeer
Summary: This study aimed to report on the efficacy, adverse events, and therapy regimens of PEG-IFN alpha in cutaneous T-cell lymphoma. Results showed that PEG-IFN alpha, especially in combination with skin-directed therapies, is an effective treatment option for cutaneous T-cell lymphoma in clinical practice.
ACTA DERMATO-VENEREOLOGICA
(2023)
Review
Dermatology
Kazuyasu Fujii
Summary: Mycosis fungoides (MF) and Sezary syndrome (SS) are representative cutaneous lymphomas, with a shift from Th1 to Th2 environment as the disease progresses. Staphylococcus aureus is highly sensitive in advanced stages, and susceptibility to infection is related to the main symptoms of MF.
JOURNAL OF DERMATOLOGY
(2022)
Article
Cell Biology
Loka Reddy Velatooru, Cheng Hui Hu, Pedram Bijani, Xiaohong Wang, Pierr Bojaxhi, Hao Chen, Madeleine Duvic, Xiao Ni
Summary: In this study, a novel JAK3-INSL3 fusion transcript was identified in cutaneous T-cell lymphomas (CTCL). Higher expression of JAK3-INSL3 was associated with poorer survival in CTCL patients. Knockdown of JAK3-INSL3 decreased cell proliferation and tumor growth.
Review
Medicine, Research & Experimental
Man Hu, Joerg Scheffel, Daniel Elieh-Ali-Komi, Marcus Maurer, Tomasz Hawro, Martin Metz
Summary: Primary cutaneous T-cell lymphomas (CTCL) are characterized by the accumulation of malignant T-lymphocytes in the skin, leading to severe pruritus that significantly impacts patients' quality of life. Understanding the underlying mechanisms of CTCL pruritus is challenging, but studies suggest that proteases (such as tryptase) and neuropeptides (particularly Substance P) may play a significant role, alongside cytokine receptors, MRGPRs, and TRP channels. Targeting these mediators and receptors could lead to effective treatment options for CTCL pruritus.
CLINICAL AND EXPERIMENTAL MEDICINE
(2023)
Article
Cell Biology
Philipp Licht, Volker Mailaender
Summary: Cutaneous T-Cell Lymphomas (CTCL) exhibit clinical variability and transcriptional heterogeneity, with different T-cell subtypes suggested as sources of the disease. The microbiome may play a role in disease progression and transcriptional heterogeneity, and microbial approaches have the potential to aid in diagnosis and treatment of CTCL.
Article
Cell Biology
Xiaotong Xue, Zhenzhen Wang, Zihao Mi, Tingting Liu, Chuan Wang, Peidian Shi, Lele Sun, Yongliang Yang, Wenchao Li, Zhe Wang, Hong Liu, Furen Zhang
Summary: Sezary syndrome, a rare and aggressive type of cutaneous T cell lymphoma, poses challenges in diagnosis and treatment due to its intra-tumoral heterogeneity and poor understanding of its pathogenesis. Single-cell transcriptomic and chromatin accessibility data analysis revealed developmental differences and specific marker genes in Sezary cells from different sources, providing insights into the diagnosis and prognosis of MF/SS. Functional experiments demonstrated that targeting inhibition of KLHL42 could be a promising therapeutic approach in CTCL.
CELL DEATH & DISEASE
(2022)
Article
Dermatology
Cosimo Di Raimondo, Sara Vaccarini, Andrea Nunzi, Vito Rapisarda, Annagiulia Zizzari, Federico Meconi, Alessandro Monopoli, Maria Grazia Narducci, Enrico Scala, Luca Bianchi, Cristiano Tesei, Maria Cantonetti
Summary: The aim of this retrospective study was to assess the efficacy of a lower dosage of gemcitabine in treating cutaneous T cell lymphomas (CTCL). The study found that the schedule of 1000 mg every 15 days had the highest efficacy and lowest toxicity profile. Gemcitabine at a lower dose showed durable response in advanced-stage and refractory CTCL patients.
DERMATOLOGIC THERAPY
(2022)
Article
Dermatology
Yuka Mizuno, Sayaka Shibata, Tomomitsu Miyagaki, Yukiko Ito, Haruka Taira, Issei Omori, Teruyoshi Hisamoto, Kenta Oka, Kazuki M. Matsuda, Hikari Boki, Naomi Takahashi-Shishido, Makoto Sugaya, Shinichi Sato
Summary: In recent years, circulating cell-free DNA (cfDNA) has gained attention as a biomarker for cancer. This study found that serum cfDNA levels in patients with cutaneous T-cell lymphoma (CTCL) were significantly higher than healthy controls and increased with disease progression. There were positive correlations between cfDNA levels and certain blood markers and clinical findings, and higher cfDNA levels were associated with a worse prognosis in CTCL patients.
JOURNAL OF DERMATOLOGY
(2022)
Review
Hematology
Pooja Virmani, Susan H. Hwang, Justin G. Hastings, Bradley M. Haverkos, Becca Kohnken, Alejandro A. Gru, Anjali Mishra, Stephanie K. Fabbro, Steve M. Horwitz, Pierluigi Porcu
EXPERT REVIEW OF HEMATOLOGY
(2017)
Article
Oncology
Bradley M. Haverkos, Ying Huang, Alejandro Gru, Preeti Pancholi, Aharon G. Freud, Anjali Mishra, Amy S. Ruppert, Robert A. Baiocchi, Pierluigi Porcu
INTERNATIONAL JOURNAL OF CANCER
(2017)
Editorial Material
Medicine, General & Internal
Pierluigi Porcu, Joya Sahu
Editorial Material
Dermatology
S. M. Matlock, J. L. Rush, W. Afzal, E. H. Fulton, S. M. Berney, H. K. Wong
CLINICAL AND EXPERIMENTAL DERMATOLOGY
(2020)
Article
Biochemical Research Methods
Mustafa Bayraktar, Sinan Kockara, Tansel Halic, Mutlu Mete, Henry K. Wong, Kamran Iqbal
BMC BIOINFORMATICS
(2019)
Article
Dermatology
Rebecca Kohnken, Betina McNeil, Jing Wen, Kathleen McConnell, Leah Grinshpun, Ashleigh Keiter, Luxi Chen, Basem William, Pierluigi Porcu, Anjali Mishra
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2019)
Article
Hematology
Stefan K. Barta, Jerald Z. Gong, Pierluigi Porcu
Editorial Material
Dermatology
P. Porcu, N. Nikbakht
BRITISH JOURNAL OF DERMATOLOGY
(2021)
Article
Oncology
Syed Jafar Mehdi, Andrea Moerman-Herzog, Henry K. Wong
Summary: Skin fibroblasts play important roles in the tumor microenvironment of MF. In co-culture models, normal and MF fibroblasts have differential effects on T-cell phenotype, modulating the expression of Th1 cytokines and CTCL biomarkers, suggesting distinct roles with implications for MF progression.
Article
Medicine, General & Internal
Appalanaidu Sasapu, Andrew L. J. Dunn, Jerad Gardner, Henry K. Wong
Summary: PC-ALCL is a rare non-Hodgkin's lymphoma with diverse clinical manifestations and histological patterns. Accurate diagnosis can be challenging, but targeted treatments, such as anti-CD30 monoclonal antibody drug conjugate, can achieve long-term clinical remission.
Article
Oncology
Xia Bi, Dania Beadle, Alexander Xu, Joseph Neff, Nicholas DeGregorio, Mouneer Odeh, Christopher McNair, Dolores Grosso, Pierluigi Porcu, Usama Gergis, Neal Flomenberg, Thomas R. Klumpp
Summary: An important obstacle in cancer research is the duplicative, poorly quality-assured, nonintercommunicating, difficult-to-access data repositories. Implementing a multipurpose cancer information system based on the BRIDG model may increase productivity and reduce costs.
JCO CLINICAL CANCER INFORMATICS
(2021)
Review
Dermatology
Sophia Ly, Dmitry Nedosekin, Henry K. Wong
Summary: Biologic therapies targeting B-cells, such as rituximab, have proven to be effective for treating immune-mediated diseases, including autoimmune skin conditions. This review provides an overview of the indications, treatment efficacy, and safety of rituximab in various autoimmune skin diseases. The data supports the use of rituximab and other B-cell-targeting therapies as alternatives or adjuncts to traditional immunosuppressants in the management of these diseases.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
(2023)
Letter
Hematology
Daniel Joffe, Safiyyah Bhatti, Lauren Banner, Romsin Zaya, Laura Gleason, Anjali Mishra, Ilan Kirsch, Pierluigi Porcu, Neda Nikbakht
Article
Hematology
Steven M. Horwitz, Raphael Koch, Pierluigi Porcu, Yasuhiro Oki, Alison Moskowitz, Megan Perez, Patricia Myskowski, Adam Officer, Jacob D. Jaffe, Sara N. Morrow, Kerstin Allen, Mark Douglas, Howard Stern, Jennifer Sweeney, Patrick Kelly, Virginia Kelly, Jon C. Aster, David Weaver, Francine M. Foss, David M. Weinstock
Review
Oncology
Fade Mahmoud, Bradley Shields, Issam Makhoul, Nathan Avaritt, Henry K. Wong, Laura F. Hutchins, Sara Shalin, Alan J. Tackett
CANCER BIOLOGY & THERAPY
(2017)